Grifols, S.A. (NASDAQ:GRFS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Grifols, S.A. (NASDAQ:GRFS) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.30.

GRFS has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th. Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 7th. JPMorgan Chase & Co. boosted their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a “neutral” rating in a research report on Tuesday, June 17th. Zacks Research upgraded shares of Grifols to a “hold” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research report on Saturday, September 27th.

Grifols Stock Performance

GRFS stock opened at $9.95 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. The company has a 50 day moving average price of $10.13 and a 200 day moving average price of $8.82. Grifols has a fifty-two week low of $6.19 and a fifty-two week high of $11.14. The stock has a market capitalization of $6.84 billion, a PE ratio of 8.50, a price-to-earnings-growth ratio of 0.34 and a beta of 0.69.

Grifols Announces Dividend

The firm also recently announced a special dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were given a dividend of $0.1404 per share. The ex-dividend date was Tuesday, August 12th. Grifols’s payout ratio is presently 11.97%.

Institutional Trading of Grifols

Institutional investors and hedge funds have recently made changes to their positions in the business. Sequoia Financial Advisors LLC raised its position in shares of Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 3,399 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Grifols by 426.1% during the first quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company’s stock worth $1,850,000 after acquiring an additional 21,128 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Grifols by 66.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 60,063 shares of the biotechnology company’s stock worth $427,000 after acquiring an additional 23,980 shares in the last quarter. Advisors Preferred LLC bought a new position in Grifols during the first quarter worth about $368,000. Finally, Vident Advisory LLC lifted its holdings in Grifols by 134.5% during the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock worth $495,000 after acquiring an additional 39,902 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.